Salarius Pharmaceuticals, Inc.SLRX
Market cap
$1.53M
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | - | - | - | - | - | 127,408 | 18,058 | 19,183 | 6,677 | 10,051 | 4,424 |
| Stock-based compensation | 1 | 7 | 7 | 4 | 2 | 751,618 | 319,391 | 559,044 | 796,803 | 524,838 | 273,730 |
| Cash from operations | -6,480,866 | -20,746,118 | -32,051,873 | -27,722,198 | -23,598,660 | -11,580,096 | -10,311,363 | -10,200,197 | -17,595,321 | -12,846,137 | -4,525,337 |
| Capital expenditures | -76,141 | -265,617 | -559,378 | -113,498 | - | - | -2,600 | - | - | - | - |
| Cash from investing | -76,141 | -27,265,091 | -12,240,880 | 24 | 14 | 6 | -2,600 | - | -1,500,000 | - | - |
| Payments for dividends | - | - | - | - | - | 133,594 | - | - | - | - | - |
| Cash from financing | 40 | 81 | 22,098 | 2,632 | 118,010 | 4 | 18 | 28 | 2 | 7 | 1 |
| Free cash flow | - | - | - | - | - | ||||||
| FCF margin (%) | - | - | - | - | - | - | - |